Finerenone: a potential treatment for patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorD'Marco Gascón, Luis Gerardo
dc.contributor.authorPuchades, María Jesús
dc.contributor.authorGandía, Lorena
dc.contributor.authorForquet, Claudia
dc.contributor.authorGiménez Civera, Elena
dc.contributor.authorPanizo, Nayara
dc.contributor.authorReque, Javier
dc.contributor.authorJuan García, Isabel
dc.contributor.authorBermúdez, Valmore
dc.contributor.authorGórriz, José Luis
dc.contributor.otherProducción Científica UCH 2021
dc.contributor.otherUCH. Departamento de Medicina y Cirugía
dc.date.accessioned2024-09-13T14:33:47Z
dc.date.available2024-09-13T14:33:47Z
dc.date.issued2021-11
dc.descriptionEste recurso está disponible en acceso abierto con la autorización de la revista o editorial.es_ES
dc.description.abstractType 2 diabetes mellitus (T2DM) affects an estimated 463 million people worldwide, equivalent to 1 in 11 adults. Moreover, the rapid growth of this disease has resulted in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main cause of chronic kidney disease (CKD). Hyperglycaemia, low-grade inflammation, altered lipid metabolism and hyperactivation of the renin–angiotensin–aldosterone system (RAAS) seem to be interrelated mechanisms contributing to both T2DM and microvascular complications. The introduction of drugs such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists has improved the ability to slow the progression of DKD, and has also demonstrated benefits in cardiovascular disease. Beyond the effects of these novel antidiabetic drugs, a body of evidence suggests that the overactivation of the mineralocorticoid receptor also contributes to CKD progression. Moreover, new and ongoing trials have demonstrated that the selective nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone improves the risk of CKD progression and cardiovascular events in patients with CKD and T2DM and optimized RAAS blockade. We review the rationale for the development and use of MRA drugs to slow CKD progression in patients with DKD, as well as other pleiotropic effects, and highlight the warnings associated with these agents.es_ES
dc.identifier.citationD'Marco, L., Puchades, M.J., Gandía, L., Forquet, C., Giménez Civera, E., Panizo, N., Reque, J., Juan García, I., Bermúdez, V. & Górriz, J.L. (2021). Finerenone: a potential treatment for patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. touchREVIEWS in Endocrinology, vol. 17, i. 2 (nov.), pp. 84–87. DOI: https://doi.org/10.17925/EE.2021.17.2.84es_ES
dc.identifier.doihttps://doi.org/10.17925/EE.2021.17.2.84
dc.identifier.issn2752-5457 (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/16161
dc.language.isoenes_ES
dc.publisherTouch Medical Mediaes_ES
dc.relation.ispartoftouchREVIEWS in Endocrinology, vol. 17, i. 2 (nov.)
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectEnfermedad cardiovasculares_ES
dc.subjectCardiovascular diseaseses_ES
dc.subjectAparato urinarioes_ES
dc.subjectUrinary systemes_ES
dc.subjectEnfermedades_ES
dc.subjectDiseaseses_ES
dc.subjectEndocrinologíaes_ES
dc.subjectEndocrinologyes_ES
dc.subjectFinerenonaes_ES
dc.subjectFinerenonees_ES
dc.subjectDiabeteses_ES
dc.titleFinerenone: a potential treatment for patients with Chronic Kidney Disease and Type 2 Diabetes Mellituses_ES
dc.typeArtículoes_ES
dspace.entity.typePublicationes

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Finerenone_DMarco_TE_2021.pdf
Size:
123.81 KB
Format:
Adobe Portable Document Format